The Antisense and RNAi Therapeutics Market Segment is poised for significant growth, projected to reach USD 18.48 billion by 2032, up from USD 4.15 billion in 2023, reflecting a robust Compound Annual Growth Rate (CAGR) of 18.05% during the forecast period from 2024 to 2032. This remarkable growth is driven by increasing investments in genetic research, advancements in RNA-based technologies,...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian